Abstract
This is a review of the effect of duloxetine on pain in pre-clinical studies as well as in clinical studies in patients with diabetic peripheral neuropathic pain (DPNP) and fibromyalgia (FM), and painful symptoms associated with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Data sources include the pre-clinical studies of duloxetine in rodent pain models, and randomized, double-blind, placebo-controlled trials of the efficacy of duloxetine (20-120 mg/day) in the management of chronic pain in DPNP and FM, and in MDD and GAD trials that included pain measures. In pre-clinical studies, duloxetine reduced pain in animal models of central and neuropathic chronic pain states. In the clinical trials, duloxetine (60-120 mg/day) significantly reduced the severity of pain in patients with DPNP and FM. In pooled analyses of the MDD and GAD studies, there was a significant main effect of treatment with duloxetine on painful symptoms. The results from these studies demonstrate that duloxetine reduces pain in pre-clinical animal studies, clinical studies of patients with FM and DPNP, and in painful symptoms associated with MDD and GAD.
Keywords: Anxiety, depression, diabetic neuropathic pain, duloxetine, fibromyalgia, pain, Chronic pain, Neuropathic Pain, generalized anxiety disorder, diabetic peripheral neuropathic pain, major depressive disorder
Current Drug Therapy
Title: Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies
Volume: 6 Issue: 2
Author(s): Michael J. Robinson, Jonna Ahl, Adam L. Meyers, Bill H. McCarberg and Smriti Iyengar
Affiliation:
Keywords: Anxiety, depression, diabetic neuropathic pain, duloxetine, fibromyalgia, pain, Chronic pain, Neuropathic Pain, generalized anxiety disorder, diabetic peripheral neuropathic pain, major depressive disorder
Abstract: This is a review of the effect of duloxetine on pain in pre-clinical studies as well as in clinical studies in patients with diabetic peripheral neuropathic pain (DPNP) and fibromyalgia (FM), and painful symptoms associated with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Data sources include the pre-clinical studies of duloxetine in rodent pain models, and randomized, double-blind, placebo-controlled trials of the efficacy of duloxetine (20-120 mg/day) in the management of chronic pain in DPNP and FM, and in MDD and GAD trials that included pain measures. In pre-clinical studies, duloxetine reduced pain in animal models of central and neuropathic chronic pain states. In the clinical trials, duloxetine (60-120 mg/day) significantly reduced the severity of pain in patients with DPNP and FM. In pooled analyses of the MDD and GAD studies, there was a significant main effect of treatment with duloxetine on painful symptoms. The results from these studies demonstrate that duloxetine reduces pain in pre-clinical animal studies, clinical studies of patients with FM and DPNP, and in painful symptoms associated with MDD and GAD.
Export Options
About this article
Cite this article as:
J. Robinson Michael, Ahl Jonna, L. Meyers Adam, H. McCarberg Bill and Iyengar Smriti, Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies, Current Drug Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157488511795304903
DOI https://dx.doi.org/10.2174/157488511795304903 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gastrointestinal Disturbances in Anorexia Nervosa and Bulimia Nervosa
Current Drug Targets - CNS & Neurological Disorders Inhibition of the Function of TRPV1-Expressing Nociceptive Sensory Neurons by Somatostatin 4 Receptor Agonism: echanism and Therapeutical Implications
Current Topics in Medicinal Chemistry Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Diabetic Neuropathy: Update on Pathophysiological Mechanism and the Possible Involvement of Glutamate Pathways
Current Diabetes Reviews Validation of Neuropad in the Assessment of Peripheral Diabetic Neuropathy in Patients with Diabetes Mellitus Versus the Michigan Neuropathy Screening Instrument, 10g Monofilament Application and Biothesiometer Measurement
Current Vascular Pharmacology HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science Ex Vivo Gene Therapy and Vision
Current Gene Therapy Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge
Current Diabetes Reviews Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal Simvastatin Nanoparticles Loaded Polymeric Film as a Potential Strategy for Diabetic Wound Healing: <i>In Vitro</i> and <i>In Vivo</i> Evaluation
Current Drug Delivery